🇨🇳 China Market Entry
China Market Entry:
Trial Deployment
Framework
Legal Review Process, Compliance Requirements & Execution Plan
📅 March 2026  |  Confidential
⚠️ The Problem
Where Things Broke Down
  • 🏢
    China team engaged local legal independently — without corporate visibility or sign-off
  • 🔇
    Corporate legal was not looped in — discovered after agreements were drafted
  • 📋
    No formalized review/approval process exists — no shared workflow, no joint sign-off protocol
  • 🔗
    Distribution chain not reviewed — NIA & distributor agreements lack corporate legal input
  • ☁️
    Salesforce/PIPL compliance not assessed — cross-border data transfers may violate Chinese law
✅ Proposed Solution
Joint Legal Review Board
  • ⚖️
    Corporate Legal + China Legal co-own all China agreements — shared accountability from day one
  • 🧑‍💼
    Single PM liaison coordinates between both legal teams — one point of contact, no crossed wires
  • 🚫
    Neither team can unilaterally approve — dual sign-off required on all material agreements
  • 🔄
    Bi-weekly sync cadence — structured reviews prevent last-minute fire drills
  • 📊
    Shared review tracker — full visibility into pipeline, status, and ownership of all items
📊 Framework
Tiered Review Framework
Decision Type China Legal Corporate Legal Approval
Local vendor/distributor contracts Drafts & reviews Reviews + approves Both Sign Off
Data processing (PIPL) Advises on local law Reviews for global compliance Both Sign Off
Trial agreements with customers Drafts local terms Reviews IP/liability/global Both Sign Off
Pricing & commercial terms Proposes Validates vs. global policy Corporate Final Say
Regulatory filings (NMPA) Leads Informed China Legal Leads
🔗 Distribution
Distribution Chain Structure
🏭
Your Company
HQ
📦
NIA
National Import Agent
🤝
Distributor(s)
Regional Partners
🏥
End Customers
Hospitals / Clinics
Key Review Items
📜 Import licenses 🌐 ICP license 🔒 IP protection ⚖️ Liability allocation 💰 Margin & transfer pricing 🚪 Termination rights 🔀 Sub-distribution 📊 Data flow (PIPL)
📝 Agreements
NIA & Distributor Key Review Areas

📦 NIA Agreement

  • Import license — valid & correct product scope
  • ICP license — required for digital services
  • Revenue flow — fee structure & payment terms
  • IP protection — ownership stays with HQ
  • Liability caps & indemnification
  • Termination rights — clean exit provisions

🤝 Distributor Agreement

  • Exclusive vs. non-exclusive territory
  • Customer ownership — who owns the relationship?
  • Data flow — PIPL compliance required
  • Sub-distribution restrictions & oversight
  • Reporting visibility — sales & customer data
  • Performance targets & minimum commitments
🔐 Data Compliance
Salesforce + PIPL Compliance
  • 🇨🇳
    PIPL = China's GDPR — fines up to ¥50M or 5% of annual revenue
  • Key issue: Where is Salesforce data hosted? — must determine before any customer data is entered
  • 🌐
    Cross-border transfer requires: Standard Contract + CAC filing or Security assessment or Certification
  • 📝
    Separate informed consent in Chinese required for cross-border data transfers

🇨🇳 China SF Instance

Salesforce on Alibaba Cloud. Cleanest PIPL compliance. Higher cost & operational complexity.

🌐 Global SF + Standard Contract

Use existing global instance. Requires Standard Contract + CAC filing. Moderate risk.

📁 Local CRM + Anonymized Sync

Local CRM for PII, sync anonymized data globally. Complex but compliant option.

🏛️ Regulatory
Regulatory Requirements
🏥

NMPA Classification

AI clinical decision support likely classified as Class II medical device. Requires registration before commercial use. China Legal to lead assessment.

🔒

Cybersecurity Review (CAC)

Products handling significant data or with national security implications require CAC security review. Mandatory for health data platforms.

🤖

Algorithm Transparency

China AI regulations (2023+) require algorithm registration, transparency disclosures, and content review for recommendation systems.

📋

Content Review

Clinical content, AI outputs, and any patient-facing materials must pass content review for sensitive topics under China's censorship framework.

⚠️ Critical Risks
Critical Compliance — Don't Forget These
🇺🇸
US Export Controls (EAR/BIS) — AI technology exported to China may require a Commerce Department export license. Assess before any product transfer.
💸
FCPA / Anti-Bribery — Hospital sales through intermediaries is a textbook FCPA risk. Due diligence on all agents/distributors is mandatory.
📍
Data Localization — Personal health data may be subject to strict localization requirements. Cannot assume offshore storage is permitted.
🔏
IP Registration — China is first-to-file. Register trademarks, patents, and copyrights in China immediately — before any public disclosure.
🚫
Content Censorship Review — Clinical AI outputs must be screened against restricted topics and content guidelines enforced in China.
📅 Phase 1 · Weeks 1–4
Phase 1 — Legal & Regulatory Foundation
Establish Joint Legal Review Board with defined decision rights
Corp + China Legal
Initiate PIPL Data Protection Impact Assessment (DPIA)
Corp Legal + IT
Request & review NIA and distributor agreement drafts
China Legal + PM
Confirm NMPA device classification with China regulatory counsel
China Legal
Run US export control analysis (EAR/BIS) with corporate legal
Corp Legal
File China trademark / IP registrations
Corp Legal
Conduct FCPA due diligence on all proposed intermediaries
Corp Legal
📅 Phase 2 · Weeks 3–6
Phase 2 — Commercial Setup
Execute reviewed & approved NIA agreement
Corp + China Legal
Execute reviewed & approved distributor agreement(s)
Corp + China Legal
Finalize transfer pricing & margin structure
Finance + Corp Legal
Draft trial agreement template for hospital/clinic customers
China Legal + PM
Define pilot site selection criteria and KOL targets
Sales + Product
Establish reporting & visibility requirements with distributors
PM + Sales
Set up shared review tracker and bi-weekly legal sync cadence
PM
📅 Phase 3 · Weeks 4–8
Phase 3 — Product & Technical
Implement data localization solution (China SF / local CRM / anonymized sync)
IT + Product
Localize product UI, documentation, and consent flows in Simplified Chinese
Product
Register algorithm with CAC and complete transparency disclosures
China Legal + Product
Validate AI outputs for content compliance with Chinese regulations
Product + China Legal
Complete hospital EHR integration scoping and technical assessment
IT + Product
Develop training materials and onboarding program for trial sites
Product + Sales
Complete cybersecurity review (CAC) for health data processing
IT + China Legal
📅 Phase 4 · Weeks 6–10
Phase 4 — Trial Launch

🏆 KOL Endorsement

  • Identify 2–3 Key Opinion Leaders at trial hospitals
  • Co-develop clinical use case narrative with KOLs
  • Secure letters of support for NMPA filing
  • Plan publications / conference presentations

📊 Success Metrics

  • Clinical outcome improvement vs. baseline
  • Daily active usage rate among clinical staff
  • Time-to-diagnosis / workflow efficiency gains
  • Net Promoter Score from trial clinicians

💬 Feedback Mechanism

  • Weekly check-ins with trial site coordinators
  • Structured in-app feedback collection
  • Monthly steering committee review
  • Issue log with SLA for resolution

🚨 Escalation Path

  • Site-level issues → PM within 24h
  • Legal / compliance issues → Joint Legal Board
  • Technical critical → IT on-call + escalation matrix
  • Commercial disputes → VP Sales + Corp Legal
📅 Phase 5 · Weeks 10+
Phase 5 — Post-Trial

📄 Results Documentation

  • Compile clinical outcomes data from all trial sites
  • Prepare regulatory-grade evidence package for NMPA
  • Document adverse events and near-misses
  • Legal review of all collected data for compliance
  • Publish trial results summary (internal)

💼 Commercial Conversion

  • Convert successful trial sites to commercial contracts
  • Negotiate pricing & volume commitments
  • Establish ongoing support SLA structure
  • Finalize NMPA filing if Class II confirmed

🎓 Lessons Learned

  • Full legal process retrospective with both teams
  • Update Joint Legal Review Board charter
  • Document PIPL / data compliance playbook
  • Evaluate distributor performance vs. targets
  • Review export control adherence
  • Update FCPA due diligence process
  • Finalize China market entry playbook for scale
📅 Timeline
12-Week Execution Timeline
W1
W2
W3
W4
W5
W6
W7
W8
W9
W10
W11
W12
Phase 1: Legal & Regulatory
Legal Foundation · Wks 1–4
Phase 2: Commercial Setup
Commercial · Wks 3–6
Phase 3: Product & Technical
Product & Tech · Wks 4–8
Phase 4: Trial Launch
Trial Launch · Wks 6–10
Phase 5: Post-Trial
Post-Trial · Wks 10+
🔵 Overlap between phases is intentional — work streams run in parallel
⚡ Critical path: Legal Foundation must complete before commercial agreements execute
🚀 Action Items
Next Steps
1
Schedule joint legal alignment meeting this week — Corporate Legal + China Legal + PM to establish the Joint Legal Review Board
2
Initiate PIPL Data Protection Impact Assessment — IT & Corporate Legal to assess current Salesforce data flow and determine compliant path
3
Request NIA & distributor agreement drafts from China team — Corporate Legal to review immediately upon receipt
4
Confirm NMPA device classification with China legal — Determines trial scope and regulatory timeline
5
Run US export control check with corporate legal — Assess EAR/BIS applicability before any product transfer to China
1 / 16
to navigate  ·  F fullscreen